- Home
- REFR vs DTIL Comparison
REFR vs DTIL Comparison
Compare REFR & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFR
- DTIL
- Stock Information
- Founded
- REFR 1965
- DTIL 2006
- Country
- REFR United States
- DTIL United States
- Employees
- REFR N/A
- DTIL N/A
- Industry
- REFR Multi-Sector Companies
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- REFR Miscellaneous
- DTIL Health Care
- Exchange
- REFR Nasdaq
- DTIL Nasdaq
- Market Cap
- REFR 49.5M
- DTIL 55.3M
- IPO Year
- REFR N/A
- DTIL 2019
- Fundamental
- Price
- REFR $1.36
- DTIL $4.90
- Analyst Decision
- REFR
- DTIL Strong Buy
- Analyst Count
- REFR 0
- DTIL 2
- Target Price
- REFR N/A
- DTIL $47.00
- AVG Volume (30 Days)
- REFR 29.8K
- DTIL 83.8K
- Earning Date
- REFR 08-07-2025
- DTIL 08-07-2025
- Dividend Yield
- REFR N/A
- DTIL N/A
- EPS Growth
- REFR N/A
- DTIL N/A
- EPS
- REFR N/A
- DTIL N/A
- Revenue
- REFR $1,222,239.00
- DTIL $1,261,000.00
- Revenue This Year
- REFR N/A
- DTIL N/A
- Revenue Next Year
- REFR N/A
- DTIL $135.19
- P/E Ratio
- REFR N/A
- DTIL N/A
- Revenue Growth
- REFR N/A
- DTIL N/A
- 52 Week Low
- REFR $0.93
- DTIL $3.61
- 52 Week High
- REFR $2.35
- DTIL $11.09
- Technical
- Relative Strength Index (RSI)
- REFR 42.95
- DTIL 52.74
- Support Level
- REFR $1.37
- DTIL $4.55
- Resistance Level
- REFR $1.44
- DTIL $5.18
- Average True Range (ATR)
- REFR 0.06
- DTIL 0.27
- MACD
- REFR 0.00
- DTIL 0.03
- Stochastic Oscillator
- REFR 40.00
- DTIL 70.53
About REFR Research Frontiers Incorporated
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.